What is XBIO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for XBIO?

P/E (TTM) is n/a and 52-week range is $1.87 to $13.93 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s XBIO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for XBIO?

The company profile lists revenue (TTM) near $3M, net income (TTM) near $-247M, EPS (TTM) near $-1.20 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Xenetic Biosciences Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Framingham, Massachusetts, US, 2.3M shares outstanding, ISIN US9840156023 when available from company profile and filing metadata.

Xenetic Biosciences Inc

$XBIO

Health Care · Biotechnology

IR Run Scenarios

$2.13

+0.47%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. The company is headquartered in Framingham, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2016-11-07. The firm is focused on advancing immuno-oncology technologies addressing difficult to treat cancers. The firm's Deoxyribonuclease (DNase) technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. The company is focused on advancing the development of its DNase technology toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the currently available therapeutic options.

Employees

Website

www.xeneticbio.com/

IPO

2016-11-07

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)